Theravance Biopharma Inc. (TBPH) Stock Price Up 3.3%
Theravance Biopharma Inc. (NASDAQ:TBPH) rose 3.3% on Monday . The company traded as high as $26.49 and last traded at $26.36, with a volume of 179,113 shares trading hands. The stock had previously closed at $25.51.
Several equities research analysts recently commented on TBPH shares. Leerink Swann started coverage on Theravance Biopharma in a report on Thursday, May 12th. They set an “outperform” rating and a $26.00 target price on the stock. Zacks Investment Research cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, April 19th. Guggenheim started coverage on Theravance Biopharma in a report on Monday, June 20th. They set a “buy” rating and a $30.00 target price on the stock. Finally, Bank of America Corp. cut Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Thursday, May 5th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $24.75.
The stock’s market cap is $1.25 billion. The company has a 50 day moving average of $23.11 and a 200 day moving average of $19.99.
Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Monday, May 9th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.96) by $0.14. The company had revenue of $18.40 million for the quarter, compared to analyst estimates of $18.69 million. Equities analysts expect that Theravance Biopharma Inc. will post ($4.24) EPS for the current year.
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.